男性性腺功能低下市场机会、成长动力、产业趋势分析及预测（2025-2034）

2024 年全球男性性腺功能低下市场价值为 40 亿美元，预计 2025 年至 2034 年的复合年增长率为 5.2%。成长的动力来自于人们对荷尔蒙失衡认识的提高、诊断能力的进步以及睪固酮缺乏症盛行率的上升。当身体无法产生足够的睪固酮或睪丸功能不正常时，就会出现这种情况，导致严重的身体、性和心理併发症。由于睪固酮在许多男性生理功能中发挥着至关重要的作用，其缺乏会对整体健康、能量水平和生活品质产生负面影响。

推动这一成长的关键因素是，越来越多的老年男性出现荷尔蒙变化，需要医疗干预。此外，医疗保健基础设施和支持性监管框架的改善使得先进的治疗方法更容易获得。正在进行的研究和开发工作正在提高治疗效果，确保更好的患者治疗结果和长期遵守规定的治疗方案。医疗保健提供者越来越关注治疗睪固酮缺乏症的创新解决方案，导致全球治疗采用率激增。

睾酮替代疗法仍然是主要的治疗方法，2024 年将产生 32 亿美元的收入。随着荷尔蒙疗法的接受度不断提高以及治疗方案的更容易获得，预计到 2034 年，这一领域的复合年增长率将达到 5.3%。睪固酮替代有助于恢復正常的荷尔蒙水平，改善性功能、肌肉量、情绪和整体健康。提供不同的给药途径，包括注射、外用凝胶和口服製剂，确保患者能够选择符合其生活方式和医疗需求的治疗方法。优惠的报销政策和保险覆盖也在推动市场扩张方面发挥了关键作用，鼓励製药公司投资研究和创新。

根据给药途径，市场分为注射疗法、外用疗法和口服疗法。注射睪固酮疗法占了 55.3% 的市场份额，到 2024 年将达到 22 亿美元。这些疗法因其能够维持稳定的荷尔蒙水平，防止可能导致情绪波动、疲劳和性慾问题的波动而受到广泛青睐。医生青睐注射剂型，因为它们可以精确调整剂量，从而製定个性化的治疗计划，优化荷尔蒙水平，同时最大限度地减少潜在的副作用。因此，患者对这些疗法的依从性仍然很高，进一步增强了市场成长。

北美继续成为领先的区域市场，2024 年创造 18 亿美元的收入，预计到 2034 年将达到 31 亿美元。美国占最大份额，2023 年贡献了 16 亿美元。患有荷尔蒙缺乏症的老龄男性数量不断增加是该地区市场需求的主要驱动力。严格的监管标准确保了高品质、安全和有效的治疗方法的可用性。此外，日益增多的宣传活动、不断增加的医疗保健支出以及医学研究的进步都在支持市场扩张。随着医疗保健提供者优先考虑以患者为中心的治疗方法，创新疗法和严格的品质控制措施将继续塑造市场格局，确保受睪固酮缺乏症影响的个人获得更好的治疗效果。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 提高认识和诊断
    • 性腺功能低下发生率上升
    • 睾酮替代疗法的进展
    • 男性健康和保健项目的成长
  • 产业陷阱与挑战
    • 安全性问题和副作用
    • 严格遵守法规
• 成长潜力分析
• 监管格局
• 管道分析
• 差距分析
• 专利分析
• 波特的分析
• PESTEL 分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：依治疗类型，2021 年至 2034 年

• 主要趋势
• 睾酮替代疗法
• 促性腺激素治疗

第六章：市场估计与预测：依管理路线，2021 年至 2034 年

• 主要趋势
• 注射剂
• 主题
• 口服

第七章：市场估计与预测：按应用，2021 年至 2034 年

• 主要趋势
• 卡尔曼症候群
• 克莱恩费尔特症候群
• 脑下垂体疾病
• 其他应用

第八章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第九章：公司简介

• AbbVie
• Bayer
• Eli Lilly and Company
• Endo Pharmaceuticals
• Ferring Holdings
• Perrigo Company
• Pfizer
• Sanofi
• Teva Pharmaceutical Industries
• Viatris

The Global Male Hypogonadism Market was valued at USD 4 billion in 2024 and is projected to grow at a CAGR of 5.2% from 2025 to 2034. The growth is driven by increasing awareness of hormonal imbalances, advancements in diagnostic capabilities, and the rising prevalence of testosterone deficiency. This condition occurs when the body fails to produce adequate testosterone or when the testes do not function properly, leading to significant physical, sexual, and psychological complications. Since testosterone plays a crucial role in numerous male physiological functions, its deficiency can negatively impact overall health, energy levels, and quality of life.

A key factor fueling this growth is the increasing number of aging men experiencing hormonal changes that require medical intervention. Additionally, improved healthcare infrastructure and supportive regulatory frameworks are making advanced therapies more accessible. Ongoing research and development efforts are enhancing treatment efficacy, ensuring better patient outcomes and long-term adherence to prescribed therapies. Healthcare providers are increasingly focusing on innovative solutions to manage testosterone deficiency, leading to a surge in treatment adoption worldwide.

Testosterone replacement therapy remains the dominant treatment approach, generating USD 3.2 billion in revenue in 2024. This segment is expected to expand at a CAGR of 5.3% through 2034, supported by the growing acceptance of hormone therapy and easier access to treatment options. Testosterone replacement helps restore normal hormone levels, improving sexual function, muscle mass, mood, and overall well-being. The availability of different administration routes, including injectables, topical gels, and oral formulations, ensures that patients can choose a treatment that aligns with their lifestyle and medical needs. Favorable reimbursement policies and insurance coverage have also played a pivotal role in driving market expansion, encouraging pharmaceutical companies to invest in research and innovation.

Based on the route of administration, the market is segmented into injectable, topical, and oral therapies. Injectable testosterone therapies accounted for a 55.3% market share, reaching USD 2.2 billion in 2024. These treatments are widely preferred for their ability to maintain stable hormone levels, preventing fluctuations that could cause mood swings, fatigue, and libido issues. Physicians favor injectable formulations due to their precision in dosage adjustments, allowing for personalized treatment plans that optimize hormone levels while minimizing potential side effects. As a result, patient adherence to these therapies remains high, further strengthening market growth.

North America continues to be a leading regional market, generating USD 1.8 billion in revenue in 2024 and expected to reach USD 3.1 billion by 2034. The U.S. accounted for the largest share, contributing USD 1.6 billion in 2023. The rising number of aging men dealing with hormonal deficiencies is a major driver of market demand in this region. Strict regulatory standards ensure the availability of high-quality, safe, and effective therapies. Additionally, growing awareness campaigns, increased healthcare spending, and advancements in medical research are supporting market expansion. As healthcare providers prioritize patient-centric treatment approaches, innovative therapies and stringent quality control measures will continue to shape the market landscape, ensuring improved outcomes for individuals affected by testosterone deficiency.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing awareness and diagnosis
    • 3.2.1.2 Rising incidence of hypogonadism
    • 3.2.1.3 Advancements in testosterone replacement therapies
    • 3.2.1.4 Growth in men’s health and wellness programs
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Safety concerns and side effects
    • 3.2.2.2 Stringent regulatory compliance
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Gap analysis
• 3.7 Patent analysis
• 3.8 Porter’s analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Testosterone replacement therapy
• 5.3 Gonadotropin therapy

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Injectable
• 6.3 Topical
• 6.4 Oral

Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Kallmann syndrome
• 7.3 Klinefelter syndrome
• 7.4 Pituitary disorders
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AbbVie
• 9.2 Bayer
• 9.3 Eli Lilly and Company
• 9.4 Endo Pharmaceuticals
• 9.5 Ferring Holdings
• 9.6 Perrigo Company
• 9.7 Pfizer
• 9.8 Sanofi
• 9.9 Teva Pharmaceutical Industries
• 9.10 Viatris